Biotech News

BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine

Brainstorm Cell Therapeutics Inc. (BCLI)Brainstorm Cell Therapeutics Inc.FDA / regulatory

BCLI (BCLI) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bcli.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BCLIBrainstorm Cell Therapeutics Inc.2026-11-16 21:01 EST

BrainStorm Cell Therapeutics Announces Third Quarter 2026 Financial Results and Provides Corporate Update

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

CGTXCognition Therapeutics2026-09-29 11:30 EST

Cognition Therapeutics Schedules a Type C Meeting with FDA to Align on Endpoints for Phase 3 Trial of Zervimesine (CT1812) in DLB

CLNNClene Inc.2026-10-19 12:00 EST

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

ANVSAnnovis Bio2026-11-20 13:00 EST

Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA

JNJJohnson & Johnson2026-10-23 11:09 EST

European Commission approves Johnson & Johnson’s TECVAYLI®▼ (teclistamab) monotherapy for relapsed/refractory multiple myeloma, expanding treatment options from first relapse

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

XENEXenon2026-09-17 20:01 EST

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

TEVATeva Pharmaceutical Industries2026-11-16 13:00 EST

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

Brainstorm Cell Therapeutics Inc.

Autologous Cell-Therapy Developer BrainStorm Cell Therapeutics is developing autologous cellular therapies for neurodegenerative diseases. Its programs use a patient's own cells to deliver neuroprotective and immunomodulatory factors in disorders characterized by progressive neuronal damage. NurOwn Technology NurOwn, also known as...

Recent company news

Stock data

Close
0.84 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States